Canonical Source · court document

Impax Laboratories, Inc. v. Federal Trade Commission — Fifth Circuit decision

This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.

Publisher: United States Court of Appeals for the Fifth Circuit
Year: 2021
Source type: court document
Source level: Primary source
Knowledge backlinks: 1

Open original source ↗ Back to Evidence Library Explore connections →

Evidence context

How this source is used

Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.

Investigation

Do pharmaceutical companies suppress inexpensive universal cures because chronic treatment is more profitable?

Qualifies

The FTC's administrative determination that Impax entered an unlawful pay-for-delay arrangement concerning the generic version of Opana ER was upheld by a federal appellate court in 2021. This establishes a concrete case of anticompetitive delayed access to an existing lower-cost drug, not evidence of a hidden effective universal cure.

Subject families

Conspiracy theories Health & medicine